![SCYNEXIS, Inc. logo](/logos/SCYX.webp)
SCYNEXIS, Inc.
NASDAQ:SCYX
Overview | Financials
Company Name | SCYNEXIS, Inc. |
Symbol | SCYX |
Currency | USD |
Price | 1.27 |
Market Cap | 48,077,755 |
Dividend Yield | 0% |
52-week-range | 1.265 - 3.66 |
Industry | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Mr. David Gonzalez Angulo M.D. |
Website | https://www.scynexis.com |
An error occurred while fetching data.
About SCYNEXIS, Inc.
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD